The federal Project Grant award of $620,371, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the voltage-sensing domain (VSD) dynamics of cardiac ion channels from the CNBD family, which play a pivotal role in regulating the electrical properties of the heart. The overarching objective is to leverage advanced biophysical techniques, including patch-clamp fluorometry, transition...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,088,500.00 in funding to The University of Iowa from April 15, 2025 to January 31, 2032. The grant supports three independent research projects focused on: 1) defining microRNA targeting events and their biological relevance in the heart, and understanding the clinical significance of SNPs that alter cardiovascular microRNA...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $721,041 to investigate the role of cardiac circadian clock misalignment in promoting ventricular arrhythmias and sudden cardiac arrest. The award will fund a combination of studies using donor human hearts and a swine model of chronic coronary artery disease to establish whether a diurnal window of arrhythmia vulnerability...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $751,747 to the University of North Carolina at Chapel Hill to conduct research on the role of the protein arginine methyltransferase CARM1 in regulating cardiomyocyte (CM) maturation. The research aims to define key factors and signaling pathways that control CM structural, functional, and electrophysiological maturation at both...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $143,829 to The University of Kentucky Research Foundation to study the circadian regulation of cardiomyocyte size and function. The primary objectives are to establish human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a model for investigating how the intrinsic cardiomyocyte circadian clock impacts cell size...
This Project Grant award of $788,513 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on understanding the mechanisms underlying the maintenance of cardiac chamber identity in zebrafish. The research aims to elucidate the genetic pathways and signaling mechanisms that reinforce ventricular cardiomyocyte identity and suppress the transition to an atrial identity. Key objectives include identifying the downstream...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $732,221 to The Johns Hopkins University to evaluate the clinical feasibility and safety of an mRNA-based biological pacemaker approach. The goal is to develop an alternative to implantable cardiac pacemakers by reprogramming ventricular myocytes to function as pacemaker cells, creating de novo cardiac pacing in vivo. The 4-year...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...
This $704,071 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to elucidate the molecular mechanisms by which mutations in the LMNA gene promote cardiac conduction disorders. The project aims to establish the pathological function of LMNA in the development of cardiac conduction disorders, which can lead to conditions like sick sinus syndrome and atrioventricular block. A key...